JP2015518880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518880A5 JP2015518880A5 JP2015515647A JP2015515647A JP2015518880A5 JP 2015518880 A5 JP2015518880 A5 JP 2015518880A5 JP 2015515647 A JP2015515647 A JP 2015515647A JP 2015515647 A JP2015515647 A JP 2015515647A JP 2015518880 A5 JP2015518880 A5 JP 2015518880A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administration
- disease
- apomorphine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000003589 local anesthetic agent Substances 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 5
- 229960004046 apomorphine Drugs 0.000 claims 5
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 230000002378 acidificating effect Effects 0.000 claims 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 208000025966 Neurological disease Diseases 0.000 claims 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims 3
- 229960005015 local anesthetics Drugs 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 208000019430 Motor disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229960003180 glutathione Drugs 0.000 claims 2
- 150000002337 glycosamines Chemical class 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- RLFYROFKMULBFJ-REOHCLBHSA-N (2s)-2-hydrazinylbutanedioic acid Chemical compound NN[C@H](C(O)=O)CC(O)=O RLFYROFKMULBFJ-REOHCLBHSA-N 0.000 claims 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 229960005274 benzocaine Drugs 0.000 claims 1
- 229960000333 benzydamine Drugs 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 229960003150 bupivacaine Drugs 0.000 claims 1
- 229960001747 cinchocaine Drugs 0.000 claims 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960003976 etidocaine Drugs 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 1
- 229960004288 levobupivacaine Drugs 0.000 claims 1
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims 1
- 229960004194 lidocaine Drugs 0.000 claims 1
- 229960003194 meglumine Drugs 0.000 claims 1
- 229960002409 mepivacaine Drugs 0.000 claims 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000005040 opiate dependence Diseases 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 229960001807 prilocaine Drugs 0.000 claims 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims 1
- 229960004919 procaine Drugs 0.000 claims 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 1
- 229960001549 ropivacaine Drugs 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000010378 sodium ascorbate Nutrition 0.000 claims 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims 1
- 229960005055 sodium ascorbate Drugs 0.000 claims 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229960002372 tetracaine Drugs 0.000 claims 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655633P | 2012-06-05 | 2012-06-05 | |
| US61/655,633 | 2012-06-05 | ||
| PCT/IL2013/050487 WO2013183055A1 (en) | 2012-06-05 | 2013-06-05 | Compositions comprising apomorphine and organic acids and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017233819A Division JP6458124B2 (ja) | 2012-06-05 | 2017-12-05 | アポモルヒネと有機酸とを含む組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518880A JP2015518880A (ja) | 2015-07-06 |
| JP2015518880A5 true JP2015518880A5 (cg-RX-API-DMAC7.html) | 2016-07-21 |
| JP6257604B2 JP6257604B2 (ja) | 2018-01-10 |
Family
ID=48790516
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515647A Expired - Fee Related JP6257604B2 (ja) | 2012-06-05 | 2013-06-05 | アポモルヒネと有機酸とを含む組成物およびその使用 |
| JP2017233819A Expired - Fee Related JP6458124B2 (ja) | 2012-06-05 | 2017-12-05 | アポモルヒネと有機酸とを含む組成物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017233819A Expired - Fee Related JP6458124B2 (ja) | 2012-06-05 | 2017-12-05 | アポモルヒネと有機酸とを含む組成物およびその使用 |
Country Status (18)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2854764B1 (en) | 2012-06-05 | 2018-12-12 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| PL3777833T3 (pl) | 2014-03-13 | 2024-03-25 | Neuroderm Ltd. | Kompozycje inhibitorów dekarboksylazy dopa |
| WO2015157212A1 (en) * | 2014-04-10 | 2015-10-15 | Us Worldmeds, Llc | Stable apomorphine composition and uses thereof |
| EP2979688A1 (en) * | 2014-08-01 | 2016-02-03 | Britannia Pharmaceuticals Limited | Composition containing Apomorphine and a Divalent Metal Cation |
| AU2015369554A1 (en) * | 2014-12-23 | 2017-08-03 | Neuroderm Ltd | Crystal forms of apomorphine and uses thereof |
| US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
| MA43042A (fr) * | 2015-09-28 | 2018-08-08 | Ever Neuro Pharma Gmbh | Composition aqueuse d'apomorphine pour une administration sous-cutanée |
| WO2018160178A1 (en) | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
| EP3650860A4 (en) * | 2017-07-06 | 2021-03-31 | Yamada, Ken-Ichi | THERAPEUTIC MEDICINAL PRODUCT FOR LIPID PEROXIDATION INDUCED DISEASES AND SCREENING METHODS FOR THERAPEUTIC MEDICINAL PRODUCTS FOR LIPID PEROXIDATION INDUCED DISEASES |
| BR112020014598A2 (pt) * | 2018-01-18 | 2020-12-08 | Leukos Biotech, S. L. | Forma cristalina de partículas sólidas cocristalinas de apomorfina·ácido palmítico |
| GB201912686D0 (en) * | 2019-09-04 | 2019-10-16 | Reown Pharma Inc | Pharmaceutical composition |
| WO2021100728A1 (ja) * | 2019-11-20 | 2021-05-27 | 塩野義製薬株式会社 | 6,7-不飽和-7-カルバモイルモルヒナン誘導体含有固形製剤 |
| JP2023505687A (ja) | 2019-12-11 | 2023-02-10 | インスピルナ,インコーポレーテッド | 癌の処置方法 |
| CN116456998A (zh) * | 2020-10-29 | 2023-07-18 | 睁开眼治疗股份有限公司 | 咖啡因组合物 |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| WO2023012736A1 (en) * | 2021-08-05 | 2023-02-09 | Zydus Lifesciences Limited | Stable pharmaceutical compositions of apomorphine |
| KR20240069750A (ko) * | 2021-09-12 | 2024-05-20 | 지엠피 바이오테크놀로지 리미티드 | 신경 장애의 치료 |
| US12508259B2 (en) | 2022-02-01 | 2025-12-30 | HUMANWELL PHARMACEUTICAL US, Inc. | Pharmaceutical formulations containing Nalbuphine |
| EP4540257A1 (en) | 2022-06-15 | 2025-04-23 | EVER Neuro Pharma GmbH | Apomorphine prodrugs and uses thereof |
| US12509343B2 (en) | 2023-02-28 | 2025-12-30 | Lear Corporation | Automated trench manufacturing and assembly for attaching trim covers to a cushion assembly |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
| US12662030B2 (en) | 2023-06-15 | 2026-06-23 | Lear Corporation | Seat assembly, clip, and method of manufacture |
| WO2026092665A1 (en) * | 2024-10-31 | 2026-05-07 | Alar Pharmaceuticals Inc. | Apomorphine salts, their formulations and uses thereof |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU72463A2 (ru) | 1947-07-03 | 1947-11-30 | М.П. Опарина | Способ получени апоморфина |
| US3936495A (en) | 1973-11-27 | 1976-02-03 | Merck & Co., Inc. | Purification process |
| SU555887A1 (ru) | 1974-01-07 | 1977-04-30 | Стабилизатор водного раствора апоморфина гидрохлорида | |
| US4241082A (en) | 1977-09-02 | 1980-12-23 | Sankyo Company Limited | Agents for promoting reproductive ability of domestic animals |
| JPS5450700A (en) | 1977-09-28 | 1979-04-20 | Sankyo Co | Glazing agent of animal leather |
| JPS6021570B2 (ja) | 1978-07-04 | 1985-05-28 | 三共株式会社 | ド−パ類の高濃度製剤の製法 |
| US4642316A (en) | 1985-05-20 | 1987-02-10 | Warner-Lambert Company | Parenteral phenytoin preparations |
| US4816568A (en) | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
| DE3779500T2 (de) | 1986-06-10 | 1993-01-21 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| US4684666A (en) | 1986-08-19 | 1987-08-04 | Haas Pharmaceuticals, Inc. | Stabilized liquid analgesic compositions |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| CA2058975C (en) | 1990-10-30 | 2000-06-06 | Shuichi Kasai | Antiinflammatory gel preparation |
| US5284512A (en) | 1991-03-06 | 1994-02-08 | Donlar Corporation | Polyaspartic acid and its salts for dispersing suspended solids |
| DE10399015I1 (de) | 1991-12-20 | 2012-05-03 | Novo Nordisk As | Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält |
| US5877176A (en) | 1991-12-26 | 1999-03-02 | Cornell Research Foundation, Inc. | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| EP0639984A1 (en) | 1992-04-07 | 1995-03-01 | Mallinckrodt Veterinary, Inc. | Lyophilized somatotropin formulations |
| GB9523833D0 (en) | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| GB9700878D0 (en) * | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| AU1917899A (en) | 1998-03-20 | 1999-10-18 | Warner-Lambert Company | Crystalline sodium phenytoin monohydrate |
| US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
| CA2327285C (en) | 1998-05-15 | 2005-06-14 | Warner-Lambert Company | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same |
| IT1303684B1 (it) | 1998-10-30 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di apomorfina in soluzione stabili nel tempo. |
| JP4959864B2 (ja) | 1998-11-11 | 2012-06-27 | 大日本住友製薬株式会社 | グルタミン酸塩含有液剤 |
| US6274168B1 (en) | 1999-02-23 | 2001-08-14 | Mylan Pharmaceuticals Inc. | Phenytoin sodium pharmaceutical compositions |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| AU3490300A (en) | 1999-03-12 | 2000-10-04 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US7479498B2 (en) | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
| US6348965B1 (en) | 1999-09-24 | 2002-02-19 | Henry Palladino | Solid state fluorescence and absorption spectroscopy |
| BR0005797A (pt) * | 2000-03-20 | 2001-10-16 | Abbott Lab | Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados |
| SE0001151D0 (sv) | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
| US20020028799A1 (en) | 2000-07-06 | 2002-03-07 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| GB0017387D0 (en) | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
| US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| US20020086876A1 (en) * | 2000-11-15 | 2002-07-04 | Ruff Dustin D. | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
| US20030119714A1 (en) | 2000-12-15 | 2003-06-26 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| ITMI20011321A1 (it) * | 2001-06-22 | 2002-12-22 | Chiesi Farma Spa | Composizione farmaceutica in forma di microemulsione atta alla somministrazione per via transdermale di apomorfina utile nel trattamento del |
| JP2005526790A (ja) | 2002-03-19 | 2005-09-08 | ミシェル ホリック | アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法 |
| BR0309113A (pt) | 2002-04-11 | 2005-02-01 | Ranbaxy Lab Ltd | Composições farmacêuticas de liberação controlada de carbidopa e levodopa e processo para a preparação das mesmas |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| JP4602903B2 (ja) | 2002-10-10 | 2010-12-22 | モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー | 抗菌活性を有する新規化合物 |
| US8075919B2 (en) | 2003-07-18 | 2011-12-13 | Baxter International Inc. | Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| US7589233B2 (en) | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
| US20050053669A1 (en) | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
| US20050090518A1 (en) | 2003-10-24 | 2005-04-28 | Nastech Pharmaceutical Company Inc. | Method for treating parkinson's disease using apomorphine and apomorphine prodrugs |
| RU2006118801A (ru) | 2003-10-31 | 2007-12-10 | Алза Корпорейшн (Us) | Композиции и лекарственные формы для усиления всасывания габапентина и прегабалина |
| GB0403938D0 (en) | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| SE0401842D0 (sv) | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| US8012481B2 (en) * | 2004-09-07 | 2011-09-06 | Universite Laval | Composition and method for inducing or restoring locomotor functions in an animal |
| HRP20160455T1 (hr) | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| WO2006037061A2 (en) | 2004-09-28 | 2006-04-06 | Farouk Karoum | Compositions and methods of using d-dopa to treat parkinson's disease |
| GB0509317D0 (en) * | 2005-05-06 | 2005-06-15 | Clarke Anthony | Pharmaceutical formulation of apomorphine |
| EP1901720A2 (en) | 2005-06-23 | 2008-03-26 | Spherics, Inc. | Improved dosage forms for movement disorder treatment |
| AU2006265113A1 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| KR101446813B1 (ko) | 2006-04-06 | 2014-10-01 | 뉴파쎄 인크. | 도파민 연관된 상태의 치료를 위한 이식체 |
| DE102006021872B4 (de) | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| KR20090057349A (ko) | 2006-05-31 | 2009-06-05 | 솔베이 파머슈티컬스 게엠베하 | 레보도파/칼비도파의 24시간의 장기간 장내투여 |
| CA2606658A1 (en) | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| TW200848063A (en) | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| WO2008143240A1 (ja) * | 2007-05-21 | 2008-11-27 | Toray Industries, Inc. | 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法 |
| RU2370261C2 (ru) * | 2007-08-03 | 2009-10-20 | Закрытое Акционерное Общество "Биокад" | Стабильная эмульсия для парентерального введения плохо растворимых в воде соединений, обладающих противоопухолевой активностью, и способ ее получения |
| EP2057982A1 (en) | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasal compositions |
| JP2012500283A (ja) | 2008-08-19 | 2012-01-05 | ノップ ニューロサイエンシーズ、インク. | (r)−プラミペキソールを使用した組成物並びにその方法 |
| US20110150946A1 (en) * | 2008-08-22 | 2011-06-23 | Al-Ghananeem Abeer M | Transdermal Delivery of Apomorphine Using Microneedles |
| CN101669925B (zh) | 2008-09-10 | 2011-08-10 | 天津药物研究院 | 干粉吸入剂、其制备方法和用途 |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| PT3192500T (pt) | 2009-05-19 | 2021-01-05 | Neuroderm Ltd | Composições para a administração contínua de inibidores da dopa decarboxilase |
| CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
| KR101187064B1 (ko) | 2010-07-18 | 2012-09-28 | 주식회사 바이오폴리메드 | 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체 |
| BR112013001422A2 (pt) | 2010-07-20 | 2019-09-24 | Phytopharm Plc | metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson |
| US10150792B2 (en) | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
| DK2640358T3 (en) | 2010-11-15 | 2018-04-16 | Neuroderm Ltd | CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA-DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS THEREOF |
| WO2012066537A2 (en) | 2010-11-15 | 2012-05-24 | Neuroderm Ltd | Compositions for transdermal delivery of active agents |
| EP2545905A1 (en) | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | A new therapeutical composition containing apomorphine as active ingredient |
| WO2013061161A2 (en) | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
| EP2854764B1 (en) | 2012-06-05 | 2018-12-12 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| WO2016042413A1 (en) | 2014-09-18 | 2016-03-24 | Neuroderm, Ltd. | Opipramol patch |
| AU2015369554A1 (en) | 2014-12-23 | 2017-08-03 | Neuroderm Ltd | Crystal forms of apomorphine and uses thereof |
-
2013
- 2013-06-05 EP EP13736976.5A patent/EP2854764B1/en not_active Not-in-force
- 2013-06-05 PL PL13736976T patent/PL2854764T3/pl unknown
- 2013-06-05 US US14/405,913 patent/US9999674B2/en not_active Expired - Fee Related
- 2013-06-05 JP JP2015515647A patent/JP6257604B2/ja not_active Expired - Fee Related
- 2013-06-05 DK DK13736976.5T patent/DK2854764T3/en active
- 2013-06-05 EP EP18202757.3A patent/EP3456315A1/en not_active Withdrawn
- 2013-06-05 CN CN201710922800.2A patent/CN107693486A/zh not_active Withdrawn
- 2013-06-05 ES ES13736976T patent/ES2715028T3/es active Active
- 2013-06-05 TR TR2019/03492T patent/TR201903492T4/tr unknown
- 2013-06-05 HU HUE13736976A patent/HUE042425T2/hu unknown
- 2013-06-05 AU AU2013273138A patent/AU2013273138B2/en not_active Ceased
- 2013-06-05 RU RU2014152208A patent/RU2688672C2/ru active
- 2013-06-05 PT PT13736976T patent/PT2854764T/pt unknown
- 2013-06-05 WO PCT/IL2013/050487 patent/WO2013183055A1/en not_active Ceased
- 2013-06-05 CN CN201380029952.XA patent/CN104349768B/zh not_active Expired - Fee Related
- 2013-06-05 NZ NZ703341A patent/NZ703341A/en not_active IP Right Cessation
- 2013-06-05 MX MX2014014902A patent/MX2014014902A/es active IP Right Grant
- 2013-06-05 CA CA2875446A patent/CA2875446A1/en not_active Abandoned
- 2013-06-05 BR BR112014030265A patent/BR112014030265A2/pt not_active Application Discontinuation
-
2014
- 2014-12-23 ZA ZA2014/09516A patent/ZA201409516B/en unknown
-
2015
- 2015-11-18 US US14/944,873 patent/US9381249B2/en not_active Expired - Fee Related
-
2017
- 2017-11-10 US US15/809,137 patent/US10525134B2/en not_active Expired - Fee Related
- 2017-12-05 JP JP2017233819A patent/JP6458124B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014152208A (ru) | Композиции, содержащие апоморфин и органические кислоты, и их применение | |
| JP2016528301A5 (cg-RX-API-DMAC7.html) | ||
| AR068512A1 (es) | Derivados de 4-aril-1h-piridin-2-onas disustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central | |
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| RU2015129546A (ru) | Нейроактивные 19-алкокси-17-замещенные стероиды, их пролекарства и способы лечения с их применением | |
| MX375731B (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn. | |
| JP2016503797A5 (cg-RX-API-DMAC7.html) | ||
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| PH12013501557A1 (en) | Glucagon receptor modulator | |
| JP2015512951A5 (cg-RX-API-DMAC7.html) | ||
| JP2017538689A5 (cg-RX-API-DMAC7.html) | ||
| DK1856045T3 (da) | 1-eddikesyreindolderviater med PGD2-antagonisteffekt | |
| MX348860B (es) | Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa. | |
| EP4603094A3 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) | |
| BR112014004963A2 (pt) | sal de colina do composto anti-inflamatório ciclobutanodiona substituído | |
| CO2018000795A2 (es) | Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido | |
| EA201401231A1 (ru) | Фармацевтические комбинации, предназначенные для лечения метаболических нарушений | |
| JP2016537338A5 (cg-RX-API-DMAC7.html) | ||
| JP2015520770A5 (cg-RX-API-DMAC7.html) | ||
| CA2873096A1 (en) | Compositions and methods for the treatment of inflammatory bowel disease | |
| RU2011147186A (ru) | 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3 | |
| WO2016103262A3 (en) | Crystal forms of apomorphine and uses thereof | |
| BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos |